2025-05-20-Jefferies-ATAI生命科学（ATAI）_5-MeO-DMT致幻剂的积极信号-_2025年年中关键IIb期数据_8页_803kb

Summary of Document: Encouraging Signal with 5-MeO-DMT (BPL-003)

Core Content

This document outlines the recent positive findings from an open-label Phase IIa study of BPL-003, an intranasal formulation of 5-MeO-DMT, in the context of treatment-resistant depression (TRD). The study results are presented as supportive of the upcoming Phase IIb trial, which is expected to provide key data in mid-2025. The report also discusses the broader implications for ATAI Life Sciences, which holds a significant stake in Beckley Psytech, the company conducting the BPL-003 trials.

Key Points

1. Phase IIa Study Results

• Study Design: Open-label, with N=12 patients.
• Efficacy: A single dose of BPL-003 led to a rapid and sustained reduction in MADRS scores:
  • -18 points after Day 1
  • -19 points after Month 1
  • -18 points after Month 3
• Baseline MADRS Score: 28.8, suggesting potential remission rates (MADRS <10) for many patients.
• Safety: AEs were mild/moderate, with no SAEs reported. Acute effects resolved within a day, and patients were dischargeable within <2 hours.
• Comparison with GH001: BPL-003's MADRS reduction appears competitive with GH001's -15.2 point reduction by Day 8 in TRD patients.

2. Phase IIb Study Overview

• Expected in Mid-2025: A randomized-controlled Phase IIb trial (N=196) will compare 8mg and 12mg doses of BPL-003 with a sub-active 0.3mg dose.
• Stock Impact: A positive outcome is expected to yield a +100% stock move for ATAI, given its ~34% stake in Beckley Psytech.
• Investor Expectation: A 5-point MADRS separation at Week 4 (primary endpoint) is anticipated for a significant stock gain.

3. Company Background: ATAI Life Sciences

• Founded in 2018: A clinical-stage company focused on mental health disorders.
• Pipeline: Includes over 10 development programs, including psychedelic compounds and enabling technologies.
• Subsidiaries: ATAI owns 50-100% equity in most of its 10 subsidiaries.
• Notable Programs:
  • Recognify Life Sciences (Phase II) evaluating RL-007 for cognitive impairment in schizophrenia.
  • COMP360 (psilocybin) in Phase III for TRD.

4. FDA and Psychedelic Development

• FDA Support: The new administration remains supportive of psychedelic development for mental health.
• Designations: Breakthrough Designation (BTD) and Special Protocol Assessments (SPAs) have been awarded to psychedelics like psilocybin, MDMA, and esketamine.
• Guidance: A 2023 guidance document was released to facilitate psychedelic research.

5. Investment Recommendation

• Rating: Buy
• Price Target: $5.00 (+172% from current price of $1.84)
• Market Cap: $336.4M
• Analysts:
  • Andrew Tsai (Equity Analyst)
  • Matthew Barcus, Ph.D. (Equity Associate)
  • John Cox, Ph.D. (Equity Associate)

6. Valuation Methodology

• Factors Considered: Market cap, maturity, growth/value, volatility, and expected total return over 12 months.
• Price Targets: Based on DCF, EBITDA, EPS, P/E, P/CF, and other financial metrics.

7. Risks and Disclosures

• Clinical Risks: Open-label design and small N=12 sample size in Phase IIa.
• Regulatory Risks: Ongoing FDA and global regulatory landscape.
• Conflict of Interest: Jefferies has investment banking relationships with ATAI, which may influence objectivity.
• Legal Restrictions: The report is not suitable for all investors and is subject to jurisdiction-specific disclosures and limitations.

Main Viewpoints

• The Phase IIa data for BPL-003 in TRD patients is encouraging and supports the upcoming Phase IIb trial.
• ATAI's stake in Beckley Psytech positions it to benefit from positive trial outcomes.
• The FDA's continued support for psychedelics in mental health is a favorable regulatory environment.
• The potential for a significant stock move is tied to the success of the Phase IIb trial.

Key Information

• Drug: BPL-003 (intranasal 5-MeO-DMT)
• Indication: Treatment-resistant depression (TRD)
• Study Phases: Phase IIa (open-label) and Phase IIb (randomized-controlled)
• Doses Tested: 10mg (in Phase IIa), 8mg and 12mg (in Phase IIb)
• AE Profile: Mild/moderate, no SAEs reported
• MADRS Reduction: -18 to -19 points at Month 3
• Investor Impact: Positive Phase IIb results could lead to a +100% stock move for ATAI
• Jefferies Disclosures: Includes potential conflicts of interest and jurisdiction-specific restrictions

Analyst Certification

All analysts certify that the views expressed in the report reflect their personal opinions and are not influenced by compensation from ATAI.

Investment Considerations

• The report is not tailored to individual investors and should be considered alongside other factors.
• Investors must evaluate their own financial situations and seek professional advice if needed.
• No guarantee of future performance or returns is made.